about
Calcium homeostasis in myogenic differentiation factor 1 (MyoD)-transformed, virally-transduced, skin-derived equine myotubesA non-invasive tissue-specific molecular delivery method of cancer gene therapy.Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapyTherapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair.Normalisation to blood activity is required for the accurate quantification of Na/I symporter ectopic expression by SPECT/CT in individual subjects.Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy.Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery?⁹⁹mTcO₄--, auger-mediated thyroid stunning: dosimetric requirements and associated molecular events.Use of suicide genes for cancer gene therapy: study of the different approaches.Bacterial gene therapy strategies.Uveal vs. cutaneous melanoma. Origins and causes of the differences.In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.Exploiting synergies between radiation and oncolytic viruses.RILES, a novel method for temporal analysis of the in vivo regulation of miRNA expression.Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology.Oncolytic viruses in radiation oncology.The Promise of Gene Therapy for Pancreatic Cancer.Genetically engineered E. coli as a protein delivery vehicle for killing cancer cells.Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach.Single-Photon Emission Computed Tomography for Preclinical Assessment of Thyroid Radioiodide Uptake Following Various Combinations of Preparative Measures.A dicistronic construct allows easy detection of human CFTR expression from YAC DNA in human cells.Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours.Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter.Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors.Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin.Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer.A new transgenic mouse line to image chemically induced p53 activation in vivo.Herpes simplex virus thymidine kinase-mediated suicide gene therapy using nano/microbubbles and ultrasound.Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors.Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo.Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice.Potential therapeutic applications of recombinant, invasive E. coli.Transient foamy virus vector production by adenovirus vectors.A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy.An element in intron 1 of the CFTR gene augments intestinal expression in vivo.Insulation of a conditionally expressed transgene in an adenoviral vector.Copy number-dependent expression of a YAC-cloned human CFTR gene in a human epithelial cell line.Changes in adenosine A1- and A2-receptor expression during adipose cell differentiation.Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II.
P50
Q28542525-CC2FA411-2522-4926-B80E-CD16C14904A0Q30356798-A723DD8E-368B-4A0B-B9D7-5A20EE96663AQ33690729-F43D321A-DC73-4548-86CD-7B56253E7013Q34209727-2CB5ADAF-B9F3-4E04-8603-594FF2D32665Q34217690-24885497-7FB4-462C-8D4B-64CF9862B111Q34656855-A59AEF7C-F8A4-4403-BA93-3CAD13B2C3A6Q34774078-02F6B1BC-C362-481E-92B6-C9411334F15CQ35129264-E8BF1D05-4BBD-4455-98F2-E62F2492B333Q35753524-D5DD9F31-94A1-4B62-ACD8-4C29A263251DQ36346126-16C0D043-D102-465B-AA67-C0C3FAB300EFQ37102764-9BB81A07-B175-4B8B-8FEF-A387B6D705E5Q37232834-006F2682-2D9D-4435-8FA9-08565F443F1AQ37236077-1DEBC886-AB67-4786-8421-0B6DB75ACED6Q37271181-63D30258-09A7-46B6-92B2-EE46410301B8Q37799393-37A45A24-07CF-48B0-B8C4-A871D1FFC47CQ37894349-25A273A3-491F-4F44-BBC1-5A219A3B0B40Q38646753-64756033-6BE5-40ED-9244-B5BCE243E2C6Q39218614-DF068100-22DA-4E1E-9CEE-6EA65FA241C3Q39520055-F51145F9-1962-428E-B724-9E7999F1538AQ39651565-C2328BF8-0AC3-45E8-A90E-211C3D5BA47EQ39721424-470B9A3C-FF13-4B99-880E-13CF1E5B227BQ39742198-46218809-E9FD-45C0-906F-8E01353028E7Q39782779-A48F7DF3-0F02-4179-A70F-0CDD85280725Q39910371-7E1C66A7-B1FF-4BC7-A6A0-893F6574578EQ39914818-880D0564-50DE-45D3-B33B-5C2A564C0E01Q39990847-692A90B3-5468-4528-A86F-762055F89424Q39996938-71EA1A05-7C1A-405E-9594-8640DC15CFAFQ40032583-2D9EBB12-9367-480A-8B85-703F30E1A28EQ40174145-9B3C9175-3931-4804-9760-12DAD18C382AQ40243243-B05D9F7B-58D5-4CCE-A782-D583CBA649B4Q40295480-E05D55D2-08BE-464F-A589-91D197B2BD12Q40534851-98E707AC-9D02-43AD-83F1-CD781DEB4D86Q40556321-63ACFF2A-7FB6-4ED6-8182-6AFFACC0D2A3Q40596831-2FF40029-550C-46AF-BDE1-71620F6BDD1BQ40697734-7E7FEE64-5C46-47F8-9969-BF124EBBC12AQ40793139-1C45C8B5-695A-4F18-8EE0-0C82FD5FF63BQ40933744-012C2184-B6A5-4BF7-989B-4EED2BD4A626Q41106470-F11D6B08-1FAE-4423-BF77-8B4E939E135FQ41221596-F082961E-62A6-4003-8E91-C8BDBCEDCE89Q41431151-3ABFD51D-B131-46DB-9B31-9A281168EE63
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Georges Vassaux
@ast
Georges Vassaux
@en
Georges Vassaux
@es
Georges Vassaux
@nl
Georges Vassaux
@sl
type
label
Georges Vassaux
@ast
Georges Vassaux
@en
Georges Vassaux
@es
Georges Vassaux
@nl
Georges Vassaux
@sl
prefLabel
Georges Vassaux
@ast
Georges Vassaux
@en
Georges Vassaux
@es
Georges Vassaux
@nl
Georges Vassaux
@sl
P1053
N-9724-2016
P106
P21
P31
P3829
P496
0000-0002-1149-7716